REGENXBIO Company Profile (NASDAQ:RGNX)

About REGENXBIO (NASDAQ:RGNX)

REGENXBIO logoREGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RGNX
  • CUSIP: N/A
  • Web: www.regenxbio.com
Capitalization:
  • Market Cap: $588.68 million
  • Outstanding Shares: 30,821,000
Average Prices:
  • 50 Day Moving Avg: $19.78
  • 200 Day Moving Avg: $19.37
  • 52 Week Range: $7.52 - $24.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.70
  • P/E Growth: 0.29
Sales & Book Value:
  • Annual Revenue: $4.65 million
  • Price / Sales: 126.60
  • Book Value: $7.04 per share
  • Price / Book: 2.71
Profitability:
  • EBIDTA: ($75,960,000.00)
  • Net Margins: -1,595.18%
  • Return on Equity: -39.52%
  • Return on Assets: -37.15%
Debt:
  • Current Ratio: 14.95%
  • Quick Ratio: 14.95%
Misc:
  • Average Volume: 241,790 shs.
  • Beta: -0.69
  • Short Ratio: 6.25
 

Frequently Asked Questions for REGENXBIO (NASDAQ:RGNX)

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Tuesday, May, 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.06. The firm earned $0.46 million during the quarter. REGENXBIO had a negative net margin of 1,595.18% and a negative return on equity of 39.52%. View REGENXBIO's Earnings History.

Where is REGENXBIO's stock going? Where will REGENXBIO's stock price be in 2017?

2 brokerages have issued twelve-month price objectives for REGENXBIO's stock. Their predictions range from $25.00 to $50.00. On average, they anticipate REGENXBIO's share price to reach $37.50 in the next twelve months. View Analyst Ratings for REGENXBIO.

Who are some of REGENXBIO's key competitors?

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the folowing people:

  • Donald J. Hayden Jr., Independent Chairman of the Board
  • Kenneth T. Mills, President, Chief Executive Officer, Executive Director
  • Vittal K. Vasista, Chief Financial Officer
  • Patrick J. Christmas, Senior Vice President, General Counsel
  • Curran M. Simpson, Senior Vice President - Technical Operations
  • Olivier Danos Ph.D., Chief Scientific Officer
  • Faraz Ali, Chief Business Officer
  • Stephen Yoo M.D., Chief Medical Officer
  • Allan M. Fox, Director
  • Daniel J. Abdun-Nabi, Independent Director

How do I buy REGENXBIO stock?

Shares of REGENXBIO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is REGENXBIO's stock price today?

One share of REGENXBIO stock can currently be purchased for approximately $19.10.


MarketBeat Community Rating for REGENXBIO (NASDAQ RGNX)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about REGENXBIO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for REGENXBIO (NASDAQ:RGNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.50 (96.34% upside)

Analysts' Ratings History for REGENXBIO (NASDAQ:RGNX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/11/2017Chardan CapitalBoost Price TargetBuy -> Buy$35.00 -> $50.00HighView Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$25.00N/AView Rating Details
4/8/2016Morgan StanleyBoost Price Target$34.00 -> $36.00N/AView Rating Details
10/12/2015Bank of America CorporationInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for REGENXBIO (NASDAQ:RGNX)
Earnings by Quarter for REGENXBIO (NASDAQ:RGNX)
Earnings History by Quarter for REGENXBIO (NASDAQ RGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.76)($0.82)$0.46 millionViewListenView Earnings Details
3/7/2017Y 2016($0.75)($0.74)$1.70 millionViewListenView Earnings Details
5/5/2016($0.40)($0.41)$0.39 millionViewN/AView Earnings Details
3/3/2016Q415($0.34)($0.20)$1.23 million$4.40 millionViewN/AView Earnings Details
11/5/2015Q315($0.35)($1.52)$1.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for REGENXBIO (NASDAQ:RGNX)
Current Year EPS Consensus Estimate: $-3.12 EPS
Next Year EPS Consensus Estimate: $-3.35 EPS

Dividends

Dividend History for REGENXBIO (NASDAQ:RGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for REGENXBIO (NASDAQ:RGNX)
Insider Ownership Percentage: 17.00%
Institutional Ownership Percentage: 67.33%
Insider Trades by Quarter for REGENXBIO (NASDAQ:RGNX)
Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)
Insider Trades by Quarter for REGENXBIO (NASDAQ:RGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Vittal VasistaCFOSell3,100$19.81$61,411.00View SEC Filing  
6/20/2017Kenneth T MillsInsiderSell6,500$19.68$127,920.00View SEC Filing  
6/15/2017Vittal VasistaCFOSell3,100$18.75$58,125.00View SEC Filing  
4/24/2017Donald J Hayden JrDirectorSell10,000$20.98$209,800.00View SEC Filing  
4/24/2017Kenneth T MillsInsiderSell15,440$20.98$323,931.20View SEC Filing  
4/24/2017Vittal VasistaCFOSell3,100$21.00$65,100.00View SEC Filing  
5/17/2016Fmr LlcInsiderSell18,300$12.41$227,103.00View SEC Filing  
5/16/2016Fmr LlcInsiderSell16,030$11.65$186,749.50View SEC Filing  
5/12/2016Fmr LlcInsiderSell6,711$10.85$72,814.35View SEC Filing  
5/11/2016Fmr LlcInsiderSell25,132$10.36$260,367.52View SEC Filing  
5/9/2016Fmr LlcInsiderSell10,570$9.94$105,065.80View SEC Filing  
5/4/2016Fmr LlcInsiderSell1,896$10.51$19,926.96View SEC Filing  
5/3/2016Fmr LlcInsiderSell6,046$10.76$65,054.96View SEC Filing  
4/29/2016Fmr LlcInsiderSell4,723$10.80$51,008.40View SEC Filing  
4/28/2016Fmr LlcInsiderSell33,196$11.23$372,791.08View SEC Filing  
4/26/2016Fmr LlcInsiderSell9,188$11.19$102,813.72View SEC Filing  
4/22/2016Fmr LlcInsiderSell20,558$11.30$232,305.40View SEC Filing  
4/20/2016Fmr LlcInsiderSell13,189$11.66$153,783.74View SEC Filing  
4/18/2016Fmr LlcInsiderSell18,900$11.75$222,075.00View SEC Filing  
4/14/2016Fmr LlcInsiderSell27,036$11.46$309,832.56View SEC Filing  
9/22/2015James E FlynnInsiderBuy175,000$22.00$3,850,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for REGENXBIO (NASDAQ:RGNX)
Latest Headlines for REGENXBIO (NASDAQ:RGNX)
Source:
DateHeadline
finance.yahoo.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : July 19, 2017
finance.yahoo.com - July 20 at 7:11 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) CFO Sells $61,411.00 in Stock
www.americanbankingnews.com - July 19 at 8:00 PM
americanbankingnews.com logo-$0.81 Earnings Per Share Expected for REGENXBIO Inc. (RGNX) This Quarter
www.americanbankingnews.com - July 17 at 10:57 AM
finance.yahoo.com logoREGENXBIO to Participate in the Piper Jaffray GenomeRx Symposium
finance.yahoo.com - July 7 at 8:22 AM
americanbankingnews.com logoInsider Selling: REGENXBIO Inc. (RGNX) Insider Sells 6,500 Shares of Stock
www.americanbankingnews.com - June 22 at 7:48 PM
finance.yahoo.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : June 21, 2017
finance.yahoo.com - June 22 at 10:44 AM
americanbankingnews.com logo Brokerages Set $37.00 Target Price for REGENXBIO Inc. (RGNX)
www.americanbankingnews.com - June 21 at 6:32 PM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Expected to Announce Earnings of -$0.81 Per Share
www.americanbankingnews.com - June 21 at 7:34 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) CFO Sells $58,125.00 in Stock
www.americanbankingnews.com - June 19 at 7:56 PM
finance.yahoo.com logoETFs with exposure to REGENXBIO, Inc. : June 15, 2017
finance.yahoo.com - June 16 at 9:21 AM
americanbankingnews.com logoShort Interest in Regenxbio Inc (RGNX) Expands By 4.6%
www.americanbankingnews.com - June 10 at 7:22 AM
finance.yahoo.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : June 8, 2017
finance.yahoo.com - June 8 at 8:38 AM
streetinsider.com logoAveXis (AVXS), REGENXBIO (RGNX) Announce New Licenses for Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
www.streetinsider.com - June 7 at 7:32 PM
finance.yahoo.com logoAveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
finance.yahoo.com - June 7 at 7:32 PM
finance.yahoo.com logoREGENXBIO and AveXis Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
finance.yahoo.com - June 7 at 7:32 PM
finance.yahoo.com logoETFs with exposure to REGENXBIO, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 8:15 PM
finance.yahoo.com logoREGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 10:47 PM
finance.yahoo.com logoREGENXBIO Announces Initiation of Phase I Clinical Trial of RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
finance.yahoo.com - May 31 at 12:50 PM
americanbankingnews.com logo Brokerages Anticipate Regenxbio Inc (RGNX) to Announce -$0.80 EPS
www.americanbankingnews.com - May 26 at 12:30 AM
finance.yahoo.com logoREGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 24 at 7:55 PM
americanbankingnews.com logo Regenxbio Inc (RGNX) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - May 12 at 10:41 PM
finance.yahoo.com logoREGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 10 at 7:44 PM
americanbankingnews.com logoRegenxbio Inc (RGNX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 6:58 PM
finance.yahoo.com logoEdited Transcript of RGNX earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 11:13 AM
finance.yahoo.com logoInvestor Network: REGENXBIO, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 7:04 PM
finance.yahoo.com logoREGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 9 at 7:04 PM
marketbeat.com logoRegenxbio reports 1Q loss
marketbeat.com - May 9 at 6:45 PM
finance.yahoo.com logoREGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : May 5, 2017
finance.yahoo.com - May 5 at 7:47 PM
finance.yahoo.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : May 4, 2017
finance.yahoo.com - May 4 at 7:45 PM
finance.yahoo.com logoPreclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences
finance.yahoo.com - May 4 at 7:45 PM
americanbankingnews.com logoRegenxbio (RGNX) Getting Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - May 3 at 2:56 PM
americanbankingnews.com logo-$0.76 Earnings Per Share Expected for Regenxbio Inc (RGNX) This Quarter
www.americanbankingnews.com - May 2 at 8:02 PM
finance.yahoo.com logoREGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 2 at 5:21 PM
americanbankingnews.com logoRegenxbio (RGNX) Earns Media Impact Rating of 0.25
www.americanbankingnews.com - April 30 at 10:36 AM
americanbankingnews.com logoRegenxbio (RGNX) Getting Somewhat Negative Press Coverage, Study Shows
www.americanbankingnews.com - April 27 at 6:48 PM
americanbankingnews.com logoVittal Vasista Sells 3,100 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - April 26 at 11:38 PM
americanbankingnews.com logoInsider Selling: Regenxbio Inc (RGNX) Director Sells 10,000 Shares of Stock
www.americanbankingnews.com - April 26 at 11:32 PM
americanbankingnews.com logoRegenxbio Inc (RGNX) Insider Kenneth T. Mills Sells 15,440 Shares
www.americanbankingnews.com - April 26 at 11:30 PM
finance.yahoo.com logoREGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - April 26 at 5:46 PM
americanbankingnews.com logoRegenxbio (RGNX) Receiving Very Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 18 at 9:24 AM
americanbankingnews.com logoChardan Capital Increases Regenxbio Inc (RGNX) Price Target to $50.00
www.americanbankingnews.com - April 17 at 7:56 AM
americanbankingnews.com logoRegenxbio (RGNX) Given Daily News Impact Score of -0.04
www.americanbankingnews.com - April 15 at 2:13 PM
americanbankingnews.com logoRegenxbio Inc (RGNX) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 15 at 7:12 AM
americanbankingnews.com logoRegenxbio Inc (RGNX) Expected to Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 13 at 12:14 PM
americanbankingnews.com logoRegenxbio Inc (RGNX) Lowered to "D+" at TheStreet
www.americanbankingnews.com - April 11 at 2:45 PM
americanbankingnews.com logoZacks: Analysts Expect Regenxbio Inc (RGNX) Will Post Earnings of -$0.76 Per Share
www.americanbankingnews.com - April 11 at 2:13 PM
streetinsider.com logoRegenxbio Inc. (RGNX) PT Raised to $50 at Chardan Capital Markets on News Dr. Olivier Danos is New CSO; 'Watershed Moment'
www.streetinsider.com - April 11 at 10:02 AM
finance.yahoo.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : April 5, 2017
finance.yahoo.com - April 7 at 12:14 PM
americanbankingnews.com logo Regenxbio Inc (RGNX) Given $30.25 Consensus Target Price by Analysts
www.americanbankingnews.com - April 6 at 8:04 AM
americanbankingnews.com logoRegenxbio Inc (RGNX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 8:29 AM

Social

Chart

REGENXBIO (RGNX) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff